Deprescribing is the planned and supervised process of stopping a medication when that medication may no longer be necessary, is causing more harm than good, or does not align with a person’s healthcare goals and treatment preferences. There has been an explosion of deprescribing research published over the last 10 years. Researchers in the field have been doing everything from evaluating deprescribing rates in usual care to studying barriers and facilitators around establishing deprescribing in routine clinical practice. More recently, interventions specifically designed to intervene on major determinants have been developed and tested. For someone new to the field (e.g., researchers new to the field, trainees, or clinicians interested in learning more about deprescribing research), it might be difficult to know where to begin in order to gain a solid grasp of the deprescribing literature.
At the 1st International Conference on Deprescribing, held in Denmark in September 2022, this author group discussed which deprescribing articles represented work that collectively provides a diverse overview of the field for newcomers. We hoped such a collection of articles would provide an overview of the breadth of work in this area and highlight seminal pieces which shaped the field. We were inspired by the success of similar lists in related fields1 and previous discussions on social media.
Our group of deprescribing experts (n=8) first generated a preliminary list of 31 possible articles, from which we aimed to narrow down to a final 10. We tasked ourselves with thinking about articles that covered a broad range of topics in the field, and articles that had the following characteristics: high impact on the field, high-level articles (such as reviews, which could provide broad overview of research on a specific topic), or studies which incorporated novel approaches. Once we generated a preliminary list, we sent out a survey asking the eight authors ““Should this article be in the Top 10?” for the 31 candidate articles. We tallied the “Yes” votes, and the ten articles with the most “Yes” votes were included in the final list. We created the following categories to group the articles under after the Top 10 were identified: “Critical concepts”, “High level overviews”, “Major trials”, “The complexity of deprescribing” and “Knowledge synthesis in deprescribing”.
There are some articles which did not make the Top 10 that some of us still felt strongly were useful for newcomers to know about. These articles offer additional insight into important concepts in the field such as design of deprescribing interventions2, countering cognitive biases related to deprescribing,3 and the consequences of polypharmacy.4 Newcomers may also want to be aware of landmark trials that have tested novel deprescribing concepts or interventions,5–7 as well as the recent focus on implementation science in the field of deprescribing,8 and the influence of health system factors on deprescribing implementation and success.9
We recognise that this list is not exhaustive by any means and is based on the opinions of a group of established researchers in the field. It is not a comprehensive list of all the important deprescribing articles. However, it provides a start-up kit for newcomers wondering “where to start?”.
Table 1.
Ten deprescribing articles for newcomers to the field.
| First author, year | Title | Comments |
|---|---|---|
| Critical concepts | ||
| Holmes 200610 | Reconsidering medication appropriateness for patients in late life | Introduction to key aspects that inform deprescribing such as time to benefit, life expectancy, goals of care, balance of benefits and harms of medications |
| Boyd 200411 | Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance | An examination of the implications of treatment guidelines for single diseases on older adults with multiple health problems |
| High level overviews | ||
| Scott 201512 | Reducing inappropriate polypharmacy: the process of deprescribing | A framework for the process of deprescribing, highlighting key steps and considerations |
| Reeve 201713 | Deprescribing: a narrative review of the evidence and practical recommendations for recognizing opportunities and taking action | Narrative review covering ‘what is deprescribing’, the potential benefits and harms, and barriers, enablers and opportunities for taking action (with references for further reading) |
| Major trials | ||
| Tannenbaum 201414 | Reduction of inappropriate benzodiazepine prescriptions among older adults through direct patient education: the EMPOWER cluster randomized trial | Trial of educating patients using a deprescribing patient empowerment intervention delivered through community pharmacies |
| Sheppard 202015 | Effect of Antihypertensive Medication Reduction vs Usual Care on Short-term Blood Pressure Control in Patients With Hypertension Aged 80 Years and Older: The OPTIMISE Randomized Clinical Trial | Contemporary trial incorporating a novel approach in the field (noninferiority) to examine the effects of deprescribing |
| The complexity of deprescribing | ||
| Doherty 202016 | Barriers and facilitators to deprescribing in primary care: a systematic review | A comprehensive review highlighting the challenges of deprescribing in routine care |
| Weir 202217 | Consumer attitudes towards deprescribing: a systematic review and meta-analysis | A summary of papers which have examined how consumers across the world feel about deprescribing |
| Knowledge synthesis in deprescribing | ||
| Gnjidic 202218 | Achieving sustainable healthcare through deprescribing | Introduction to and synthesis of a collection of Cochrane Reviews related to deprescribing that discusses the challenges of evidence synthesis in this field |
| Farrell 201619 | Methodology for developing deprescribing guidelines: using evidence and GRADE to guide recommendations for deprescribing | A framework for synthesizing deprescribing evidence into clinical practice guidelines for clinicians and patients, see deprescribing.org for related work |
Disclosures:
Authors on this article have authored and collaborated with authors of several of the studies mentioned in this commentary. Dr Reeve is supported by an NHMRC Investigator Grant (GNT1195460) and grants from the National Institute on Aging (R33-AG057289 and R01-AG070047-01). She also receives royalties for co-authoring a chapter on deprescribing in UpToDate and honorarium from the Society of Hospital Pharmacists of Australia (leading workshops on deprescribing). Sion Scott has/has had research collaborations with INVISIO Pharmaceuticals, Desitin Pharma and iEthico but has no financial interest in the organisations. Michael A. Steinman is supported by grants from the US National Institute on Aging (R24AG064025, K24AG049057, P30AG044281) and receives honoraria from the American Geriatrics Society and from UpToDate for chapter authorship. Dr. McDonald is the creator and owner of the software MedSafer, licensed for used by MedSafer Corp. MedSafer provides electronic decision support for deprescribing. Dr. Farrell has received honoraria from the American College of Clinical Pharmacy for a textbook chapter and from the United States Deprescribing Research Network as a Scientific Advisory Board Member. Dr. Thompson has received a grant from the US Deprescribing Network (US National Institute on Aging).
References
- 1.Pottegård A, Morin L, Hallas J, et al. Where to begin? Thirty must-read papers for newcomers to pharmacoepidemiology. Pharmacoepidemiol Drug Saf. 2022;31(2):257–259. doi: 10.1002/pds.5382 [DOI] [PubMed] [Google Scholar]
- 2.Isenor JE, Bai I, Cormier R, et al. Deprescribing interventions in primary health care mapped to the Behaviour Change Wheel: A scoping review. Research in Social and Administrative Pharmacy. Published online September 2020. doi: 10.1016/j.sapharm.2020.09.005 [DOI] [PubMed] [Google Scholar]
- 3.Scott IA, Soon J, Elshaug AG, Lindner R. Countering cognitive biases in minimising low value care. Medical Journal of Australia. 2017;206(9):407–411. doi: 10.5694/mja16.00999 [DOI] [PubMed] [Google Scholar]
- 4.Wastesson JW, Morin L, Tan ECK, Johnell K. An update on the clinical consequences of polypharmacy in older adults: a narrative review. Expert Opin Drug Saf. 2018;17(12):1185–1196. doi: 10.1080/14740338.2018.1546841 [DOI] [PubMed] [Google Scholar]
- 5.Kutner JS, Blatchford PJ, Taylor DH, et al. Safety and benefit of discontinuing statin therapy in the setting of advanced, life-limiting illness a randomized clinical trial. JAMA Intern Med. 2015;175(5):691–700. doi: 10.1001/jamainternmed.2015.0289 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Bayliss EA, Shetterly SM, Drace ML, et al. Deprescribing Education vs Usual Care for Patients With Cognitive Impairment and Primary Care Clinicians. JAMA Intern Med. 2022;182(5):534. doi: 10.1001/jamainternmed.2022.0502 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.McDonald EG, Wu PE, Rashidi B, et al. The MedSafer Study—Electronic Decision Support for Deprescribing in Hospitalized Older Adults. JAMA Intern Med. 2022;182(3):265. doi: 10.1001/jamainternmed.2021.7429 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Steinman MA, Boyd CM, Spar MJ, Norton JD, Tannenbaum C. Deprescribing and deimplementation: Time for transformative change. J Am Geriatr Soc. 2021;69(12):3693–3695. doi: 10.1111/jgs.17441 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Sawan M, Reeve E, Turner J, et al. A systems approach to identifying the challenges of implementing deprescribing in older adults across different health-care settings and countries: a narrative review. Expert Rev Clin Pharmacol. 2020;13(3):233–245. doi: 10.1080/17512433.2020.1730812 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Holmes HM, Hayley DC, Alexander GC, Sachs GA. Reconsidering medication appropriateness for patients late in life. Arch Intern Med. 2006;166(6):605–609. doi: 10.1001/archinte.166.6.605 [DOI] [PubMed] [Google Scholar]
- 11.Boyd CM, Darer J, Boult C, Fried LP, Boult L, Wu AW. Clinical Practice Guidelines and Quality of Care for Older Patients With Multiple Comorbid Diseases. JAMA. 2005;294(6):716. doi: 10.1001/jama.294.6.716 [DOI] [PubMed] [Google Scholar]
- 12.Scott IA, Hilmer SN, Reeve E, et al. Reducing inappropriate polypharmacy: the process of deprescribing. JAMA Intern Med. 2015;175(5):827–834. doi: 10.1001/jamainternmed.2015.0324 [DOI] [PubMed] [Google Scholar]
- 13.Reeve E, Thompson W, Farrell B. Deprescribing: A narrative review of the evidence and practical recommendations for recognizing opportunities and taking action. Eur J Intern Med. 2017;38:3–11. doi: 10.1016/j.ejim.2016.12.021 [DOI] [PubMed] [Google Scholar]
- 14.Tannenbaum C, Martin P, Tamblyn R, Benedetti A, Ahmed S. Reduction of inappropriate benzodiazepine prescriptions among older adults through direct patient education: the EMPOWER cluster randomized trial. JAMA Intern Med. 2014;174(6):890–898. doi: 10.1001/jamainternmed.2014.949 [DOI] [PubMed] [Google Scholar]
- 15.Sheppard JP, Burt J, Lown M, et al. Effect of Antihypertensive Medication Reduction vs Usual Care on Short-term Blood Pressure Control in Patients With Hypertension Aged 80 Years and Older. JAMA. 2020;323(20):2039. doi: 10.1001/jama.2020.4871 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Doherty AJ, Boland P, Reed J, et al. Barriers and facilitators to deprescribing in primary care: a systematic review. BJGP Open. 2020;4(3):bjgpopen20X101096. doi: 10.3399/bjgpopen20X101096 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Weir KR, Ailabouni NJ, Schneider CR, Hilmer SN, Reeve E. Consumer Attitudes Towards Deprescribing: A Systematic Review and Meta-Analysis. The Journals of Gerontology: Series A 2022;77(5):1020–1034. doi: 10.1093/gerona/glab222 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Gnjidic D, Johansson M, Meng DM, Farrell B, Langford A, Reeve E. Achieving sustainable healthcare through deprescribing. Cochrane Database of Systematic Reviews. 2022;2022(10). doi: 10.1002/14651858.ED000159 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Farrell B, Pottie K, Rojas-Fernandez CH, Bjerre LM, Thompson W, Welch V. Methodology for developing deprescribing guidelines: Using evidence and GRADE to guide recommendations for deprescribing. PLoS One. 2016;11(8). doi: 10.1371/journal.pone.0161248 [DOI] [PMC free article] [PubMed] [Google Scholar]
